Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02924571 · ClinicalTrials.gov registry record · NA
BMAC & Allograft vs BMP-2
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
NCT02924571: Completed NA study, sponsored by NYU Langone Health.
NCT02924571 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 59 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02924571, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
Study Summary
The aim of this investigation is to compare the use of bone marrow aspirate concentrate (BMAC) and allograft versus recombinant human bone morphogenetic protein-2 (BMP) versus the gold standard fusion in subjects undergoing elective lumbar spinal fusion with interbody support. The safety and efficacy of the surgical interventions will be evaluated by assessing fusion status and subjects' quality of life outcomes.
Primary Outcome
Fusion status assessed via CT scan by an independent radiologist.
Interventions
- PROCEDURE Autograft
- DEVICE Bone Marrow Aspirate Concentrate (BMAC) + Allograft
- DEVICE Recombinant Human Bone Morphogenetic Protein-2 (BMP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2018-07-24 |
| Est. Completion | 2024-06-03 |
| Phase | NA |
What the finished NCT02924571 record still lists
NCT02924571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Autograft is the first listed.
NCT02924571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02924571 about?
NCT02924571 is a clinical study titled "BMAC & Allograft vs BMP-2". The aim of this investigation is to compare the use of bone marrow aspirate concentrate (BMAC) and allograft versus recombinant human bone morphogenetic protein-2 (BMP) versus the gold standard fusion in subjects undergoing elective lumbar spinal fusion with interbody support. The safety and efficac...
What is the current status of trial NCT02924571?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2018-07-24. Estimated completion is 2024-06-03.
What interventions are being tested in trial NCT02924571?
The interventions under investigation include: Autograft (PROCEDURE), Bone Marrow Aspirate Concentrate (BMAC) + Allograft (DEVICE), Recombinant Human Bone Morphogenetic Protein-2 (BMP) (DEVICE).
Who is sponsoring clinical trial NCT02924571?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02924571's enrollment target sits among peer trials
59 1256th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI